Gracell Biotechnologies Inc.

AstraZeneca already considers China one of its most important markets and is increasing its focus there, announcing a $2.5bn research and development investment in Beijing along with three partnership

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

BioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou

Many countries have already realized the value of the biotech industry and are now aggressively trying to attract foreign companies in this space. But South Korea needs to up the pace to improve regul